Ligands of Immunopharmacology

RDR 03785 is a covalent MIF inhibitor with an IC 50 of 0.36 μM.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.Form:Solid

Rebamipide mofetil is an orally active proagent of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.

RIG012 is a potent RIG-I inhibitor with an IC 50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.In VitroRIG012 contains a strong chromophore that absorbs in the visible range (λmax of 470 nm). Upon

RIG012 is a potent RIG-I inhibitor with an IC 50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.In VitroRIG012 contains a strong chromophore that absorbs in the visible range (λmax of 470 nm). Upon

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.In VitroRosmanol exhibits the strongest inhibition on cell viability

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.In VitroRosmanol exhibits the strongest inhibition on cell viability

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.In VitroRosmanol exhibits the strongest inhibition on cell viability